Press Releases
-
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
-
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
-
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
Spotlight
The Complexities of Gene Therapy Manufacturing
Learn more about what goes into manufacturing gene therapies and Sarepta’s approach to meeting the challenges inherent in making these transformative therapies a reality for patients with rare diseases.
Highlights
Our FDA-Approved Treatments
Learn more about our FDA-approved treatments.
A Day in The Life at Sarepta
Hear from employees and how our mission drives their work.
